Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer

Fig. 2

Antiproliferative activity of inhibitors in HER2-postive gastric cancer cell lines. BEZ235 showed superior inhibitory activity against NCI-N87 and SNU216 cells compared to trastuzumab, Everolimus, or AZD6244 (ab). Moreover, the synergism was only observed in the combination of trastuzumab with BEZ235 (P = 0.000 for all) (c and d), and not in the combination of trastuzumab with Everolimus or AZD6244 (eh). Proliferation assays are expressed as the Mean ± S.D of three replicate assays. P values calculated by factorial analysis

Back to article page